TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36931426

Group type: EXPERIMENTAL
Intervention: Rapid procedure (RP) for XR-NTX initiation
Number of subjects: 450

Group type: COMPARATOR
Intervention: Standard procedure (SP) for XR-NTX initiation
Number of subjects: 450
Study: 36931453

Group type: EXPERIMENTAL
Intervention: 20 breaths per minute
Number of subjects: 46

Group type: COMPARATOR
Intervention: 10 breaths per minute
Number of subjects: 46
Study: 36931460

Group type: EXPERIMENTAL
Intervention: OaSiS intervention
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1094
Study: 36931576

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study: 36931614

Group type: EXPERIMENTAL
Intervention: Standard Operating Procedures (SOPs) for liquid biopsy management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Critical review of existing SOPs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Developed SOPs in the RENOVATE study
Number of subjects: 0
Study: 36931672

Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical management
Number of subjects: 0
Study: 36931680

Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids (CCS) administration
Number of subjects: 1800
Study: 36931682

Group type: EXPERIMENTAL
Intervention: D2B programme 'Kilkari'
Number of subjects: 5095
Study: 36931693

Group type: EXPERIMENTAL
Intervention: tofacitinib 5 or 10 mg two times a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: TNF inhibitors (TNFi)
Number of subjects: 0
Study: 36931746

Group type: EXPERIMENTAL
Intervention: Co-extrusion of ferric pyrophosphate (FePP) with citric acid/trisodium citrate (CA/TSC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Co-extrusion of FePP with solubilizers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zinc oxide (ZnO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FePP + CA/TSC
Number of subjects: 0
Study: 36931755

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST) over 2 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 70
Study: 36931805

Group type: EXPERIMENTAL
Intervention: Pitolisant (5 mg to 40 mg daily for 4 weeks)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Pitolisant
Number of subjects: 110
Study: 36931829

Group type: EXPERIMENTAL
Intervention: Brief family-involved treatment (B-FIT)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 6
Study: 36931838

Group type: EXPERIMENTAL
Intervention: Neurocognition
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Symptom Severity
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Functioning
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Social Cognition
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Predictors of Functioning
Number of subjects: 66
Study: 36932165

Group type: EXPERIMENTAL
Intervention: Donor-derived natural killer cell infusion (DNKI)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no DNKI)
Number of subjects: 76
Study: 36932213

Group type: EXPERIMENTAL
Intervention: Individualised modality (starting with a knee joint flexion angle of 90°)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standardised modality (starting from a conventional chair with 46 cm seat height)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Individualised modality
Number of subjects: 30
Study: 36932262

Group type: EXPERIMENTAL
Intervention: 2-h pre-dose fast followed by a 30-min post-dose fast (2 h-30 min)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 4-h pre-dose fast followed by a 30-min post-dose fast (4 h-30 min)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 6-h pre-dose fast followed by a 30-min post-dose fast (6 h-30 min)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 2-h pre-dose fast followed by an overnight post-dose fast (2 h-night)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Overnight pre-dose fast followed by a 30-min post-dose fast (night-30 min)
Number of subjects: 156
Study: 36932321

Group type: EXPERIMENTAL
Intervention: Telephone and online problem-solving intervention
Number of subjects: 290

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 290
Study: 36932346

Group type: EXPERIMENTAL
Intervention: Co-administration of MMR and YF vaccines
Number of subjects: 738
Study: 36932356

Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Combined groups (Aflibercept and Ranibizumab)
Number of subjects: 47
Study: 36932361

Group type: EXPERIMENTAL
Intervention: Inotersen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36932369

Group type: EXPERIMENTAL
Intervention: PrEP for Health intervention (multicomponent behavioral intervention including tailored HIV and PrEP education, motivational interviewing, problem-solving skills, and ongoing navigation support)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced standard of care (eSOC) control condition (brief educational video on the utility of PrEP for HIV prevention)
Number of subjects: 0
Study: 36932416

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 58
Study: 36932430

Group type: EXPERIMENTAL
Intervention: Broad-Minded Affective Coping (BMAC) plus risk assessment and signposting
Number of subjects: 66

Group type: COMPARATOR
Intervention: Risk assessment and signposting alone
Number of subjects: 66
Study: 36932433

Group type: EXPERIMENTAL
Intervention: RA-ILD
Number of subjects: 148
Study: 36932645

Group type: EXPERIMENTAL
Intervention: Hyperspectral Imaging (HSI)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 341
Study: 36932709

Group type: EXPERIMENTAL
Intervention: UNTOUCHED-like programming of detection cut-offs adopted in 426 (29%) patients immediately after device implantation.
Number of subjects: 1468

Group type: EXPERIMENTAL
Intervention: UNTOUCHED-like programming of detection cut-offs adopted in 714 (49%) patients at the last follow-up.
Number of subjects: 1468

Group type: EXPERIMENTAL
Intervention: Median programmed conditional zone cut-off set to 200 bpm (IQR: 200-220) and shock zone cut-off set to 230 bpm (IQR: 210-250) at implantation.
Number of subjects: 1468
Study: 36932714

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOACs) management with interruption 52 (IQR 37-62) hours before the procedure and resumption 31 (IQR 21-47) hours later.
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOACs) management with interruption and high CHA2DS2-VASc score.
Number of subjects: 789
Study: 36932839

Group type: COMPARATOR
Intervention: PCR-confirmed infection with Yersinia spp. (2% in patients without appendicitis)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Serologic-confirmed infection with Y. enterocolitica
Number of subjects: 224

Group type: COMPARATOR
Intervention: PCR-confirmed infection with Campylobacter spp.
Number of subjects: 224
Study: 36933004

Group type: EXPERIMENTAL
Intervention: Home use of misoprostol (up to 70 days of gestation)
Number of subjects: 273
Study: 36933057

Group type: EXPERIMENTAL
Intervention: Standard Group Lifestyle Balance intervention (GLB)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Adaptive GLB Plus intervention (GLB+)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Both groups (GLB and GLB+)
Number of subjects: 184
Study: 36933080

Group type: EXPERIMENTAL
Intervention: High exposure to anticholinergic and sedative medications (DBI ≥ 1)
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: Low exposure to anticholinergic and sedative medications (0 < DBI < 1)
Number of subjects: 721

Group type: COMPARATOR
Intervention: No exposure to anticholinergic and sedative medications (DBI = 0)
Number of subjects: 721
Study: 36933101

Group type: EXPERIMENTAL
Intervention: Handbook intervention for parents; sent in June before students' August matriculation, with motivational interviewing support.
Number of subjects: 919

Group type: COMPARATOR
Intervention: Control condition (treatment as usual).
Number of subjects: 919
Study: 36933251

Group type: EXPERIMENTAL
Intervention: Early mobilization protocol (head-of-bed elevation within the first 12 hours, followed by sedation, orthostatism, and/or walking as tolerated)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Bed rest protocol (recumbent with head-of-bed angle inferior to 30° for 48 hours)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Early mobilization protocol
Number of subjects: 208

Group type: COMPARATOR
Intervention: Bed rest protocol
Number of subjects: 208
Study: 36933290

Group type: EXPERIMENTAL
Intervention: Cash incentives with InSHAPE+Weight Watchers program
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: Cash incentives with other healthy lifestyle programs (gym membership, Weight Watchers membership, InSHAPE program)
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: InSHAPE+Weight Watchers group receiving additional cash incentives
Number of subjects: 1348
Study: 36933351

Group type: EXPERIMENTAL
Intervention: Continuous reference ranges for body composition parameters
Number of subjects: 1958
Study: 36933552

Group type: EXPERIMENTAL
Intervention: RPM with care coordination
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: RPM alone
Number of subjects: 834

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 834
Study: 36933755

Group type: EXPERIMENTAL
Intervention: G1T48 (SERD) combined with N-heterocyclic carbene gold(I) [NHC-Au(I)]
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Complex 23 (G1T48 + NHC-Au(I))
Number of subjects: 1
Study: 36933767

Group type: EXPERIMENTAL
Intervention: Severe neurodevelopmental impairment (NDI)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Mild-to-moderate neurodevelopmental impairment (NDI)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Adverse outcome (perinatal death or NDI)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Behavioral problems
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Special needs education attendance
Number of subjects: 44
Study: 36933773

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (usual clinical care)
Number of subjects: 0
Study: 36933790

Group type: EXPERIMENTAL
Intervention: Low-calorie diet
Number of subjects: 42

Group type: COMPARATOR
Intervention: Ad-libitum feeding
Number of subjects: 42
Study: 36934142

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g intravenously)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 27
Study: 36934202

Group type: EXPERIMENTAL
Intervention: Deep-learning-based contrast-boosting algorithm on double-low-dose CT (DLD-DL)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard-dose CT (SD)
Number of subjects: 68
Study: 36934257

Group type: EXPERIMENTAL
Intervention: Guadecitabine in combination with ICBs (anti-CTLA-4 and anti-PD-1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guadecitabine with ICBs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guadecitabine
Number of subjects: 0
Study: 36934276

Group type: EXPERIMENTAL
Intervention: Chole-risk score
Number of subjects: 1253

Group type: EXPERIMENTAL
Intervention: POSSUM Physiological Score (PS)
Number of subjects: 1253

Group type: EXPERIMENTAL
Intervention: Chole-POSSUM score (cutoff of 25)
Number of subjects: 1253

Group type: EXPERIMENTAL
Intervention: Overall morbidity and mortality
Number of subjects: 1253
Study: 36934286

Group type: EXPERIMENTAL
Intervention: Constrained liner (CL)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Dual mobility cup (DM)
Number of subjects: 146
Study: 36934327

Group type: EXPERIMENTAL
Intervention: First-line Infliximab (FL-IFX), five 5-mg/kg infusions over 22 weeks
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional therapy (CONV), exclusive enteral nutrition or oral prednisolone
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: First-line Infliximab (FL-IFX)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional therapy (CONV)
Number of subjects: 86
Study: 36934341

Group type: EXPERIMENTAL
Intervention: interprof ACT
Number of subjects: 643

Group type: COMPARATOR
Intervention: usual care (control)
Number of subjects: 643
Study: 36934366

Group type: EXPERIMENTAL
Intervention: Danavorexton (TAK-925) 0.1 mg/kg
Number of subjects: 2
Study: 36934371

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36934668

Group type: EXPERIMENTAL
Intervention: Propolis (400 mg/day) for two months
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (400 mg/day) for two months
Number of subjects: 19
Study: 36934731

Group type: COMPARATOR
Intervention: PCV13 14-week 1+1 group
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: PCV13 2+1 group
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: PCV10 14-week 1+1 group
Number of subjects: 600

Group type: COMPARATOR
Intervention: PCV10 2+1 group
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: PCV13 1+1 groups
Number of subjects: 600
Study: 36934733

Group type: EXPERIMENTAL
Intervention: MV-LASV (low-dose group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MV-LASV (high-dose group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 36934740

Group type: EXPERIMENTAL
Intervention: Semaglutide 2·4 mg once weekly
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 36934894

Group type: EXPERIMENTAL
Intervention: MRI-guided SBRT to the prostate bed (30-34 Gy in five fractions)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Adaptive planning following initial treatment plans
Number of subjects: 31
Study: 36934978

Group type: EXPERIMENTAL
Intervention: Posterior pericardiotomy
Number of subjects: 387
Study: 36934980

Group type: EXPERIMENTAL
Intervention: Optimized mean arterial pressure (MAP) management
Number of subjects: 1100

Group type: COMPARATOR
Intervention: MAP of 65 mm Hg or more (Control)
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Optimized MAP management
Number of subjects: 1100
Study: 36934987

Group type: EXPERIMENTAL
Intervention: Autonomic regulation therapy (ART) utilizing cervical vagus nerve stimulation (VNS)
Number of subjects: 52
Study: 36935024

Group type: EXPERIMENTAL
Intervention: Low-dose whole brain radiation therapy (LD-WBRT) at 2 Gy × 5 over 1 week
Number of subjects: 5
Study: 36935089

Group type: EXPERIMENTAL
Intervention: Multi-faceted computerized antimicrobial stewardship intervention
Number of subjects: 2470

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2470
Study: 36935199

Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF) with connective tissue graft (CTG)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Tunnel technique (TUN) with connective tissue graft (CTG)
Number of subjects: 28
Study: 36935288

Group type: EXPERIMENTAL
Intervention: DNA plasmid encoding HIV-1 subtype B nef/tat/vif and env (n=11)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (n=3)
Number of subjects: 14
Study: 36935691

Group type: EXPERIMENTAL
Intervention: Nurses' education on delirium control
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Nurses' assessment practices
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Factors associated with nurses' knowledge
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Barriers to effective delirium control
Number of subjects: 371
Study: 36936230

Group type: EXPERIMENTAL
Intervention: Radspherin® administered intraperitoneally 2 days after CRS-HIPEC; dose escalation at 1-2-4-7 MBq; evaluated for safety and tolerability.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Radspherin®
Number of subjects: 23
Study: 36936243

Group type: EXPERIMENTAL
Intervention: RTA test
Number of subjects: 150
Study: 36936402

Group type: EXPERIMENTAL
Intervention: 1 g C19-IG20%
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: 2 g C19-IG20%
Number of subjects: 461

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 461
Study: 36936523

Group type: EXPERIMENTAL
Intervention: Self-directed home therapy adherence combined with TheraBracelet (subsensory random-frequency vibratory stimulation)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 12
Study: 36936551

Group type: EXPERIMENTAL
Intervention: JET + PCB
Number of subjects: 40

Group type: COMPARATOR
Intervention: PTA + PCB
Number of subjects: 40
Study: 36936553

Group type: EXPERIMENTAL
Intervention: In-hospital supplemental oxygen
Number of subjects: 2187

Group type: EXPERIMENTAL
Intervention: No intensive care unit admission
Number of subjects: 2187

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 2187

Group type: EXPERIMENTAL
Intervention: Gastrointestinal haemorrhage
Number of subjects: 2187

Group type: EXPERIMENTAL
Intervention: Thromboembolic event
Number of subjects: 2187

Group type: EXPERIMENTAL
Intervention: Congestive heart failure
Number of subjects: 2187

Group type: EXPERIMENTAL
Intervention: Subphenotype with most severe hospital course
Number of subjects: 2187

Group type: EXPERIMENTAL
Intervention: Intermediate severity subphenotype with more comorbidities
Number of subjects: 2187

Group type: EXPERIMENTAL
Intervention: Overall persistent symptoms
Number of subjects: 2187

Group type: EXPERIMENTAL
Intervention: Functional status
Number of subjects: 2187
Study: 36936918

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-specific antiviral immunity transfer from HCT donors (vaccinated or with a history of COVID-19)
Number of subjects: 0
Study: 36936925

Group type: EXPERIMENTAL
Intervention: Ig fractions from patients with AIS during COVID-19
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Polyclonal anti-β2-GPI IgG
Number of subjects: 70
Study: 36936952

Group type: EXPERIMENTAL
Intervention: 3-month interval between second and third doses of COVID-19 vaccine
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: 5-month interval between second and third doses of COVID-19 vaccine
Number of subjects: 171

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Both cohorts (3-month and 5-month intervals)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: NAb seroconversion
Number of subjects: 171
Study: 36937103

Group type: EXPERIMENTAL
Intervention: High frequency rTMS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 0
Study: 36937520

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 36937712

Group type: EXPERIMENTAL
Intervention: TAU+CBT4CBT
Number of subjects: 0

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 0
Study: 36937864

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36937912

Group type: EXPERIMENTAL
Intervention: Preoperative psychological intervention (EXPECT), adapted to be brief for integration into routine care.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified, details not available.
Number of subjects: 0
Study: 36937990

Group type: EXPERIMENTAL
Intervention: TACE + CRT (arm B)
Number of subjects: 120

Group type: COMPARATOR
Intervention: TACE (arm A)
Number of subjects: 120
Study: 36938082

Group type: EXPERIMENTAL
Intervention: Basic handgrip exercise program (group A)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Advanced handgrip exercise program (group B)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Advanced-plus upper arm banding program (group C)
Number of subjects: 119
Study: 36938380

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Present-centered group therapy (PCGT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mindfulness-based practices
Number of subjects: 0
Study: 36938582

Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Fasting glucose
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: 2-hour glucose
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: OGTT or HbA1c
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Fasting glucose and HbA1c
Number of subjects: 420
Study: 36938587

Group type: EXPERIMENTAL
Intervention: MRI and continuous glucose monitoring (CGM)
Number of subjects: 91

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Combined pancreas size and shape analysis
Number of subjects: 91
Study: 36938627

Group type: EXPERIMENTAL
Intervention: Novel sleep-wake classifier
Number of subjects: 31
Study: 36938756

Group type: EXPERIMENTAL
Intervention: Clinical screening intervention for DCM risk management
Number of subjects: 1241

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 1241
Study: 36938985

Group type: EXPERIMENTAL
Intervention: Single-shot caudal anaesthesia with 0.8 ml kg -1 of 2 mg kg -1 bupivacaine solution (group L, n = 29)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Single-shot caudal anaesthesia with 1.25 ml kg -1 of 2 mg kg -1 bupivacaine solution (group H, n = 29)
Number of subjects: 58
Study: 36939067

Group type: EXPERIMENTAL
Intervention: V114 (15-valent pneumococcal conjugate vaccine)
Number of subjects: 407

Group type: COMPARATOR
Intervention: PCV13 (13-valent pneumococcal conjugate vaccine)
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: V114 followed by PPSV23
Number of subjects: 407

Group type: COMPARATOR
Intervention: PCV13 followed by PPSV23
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: V114
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: PPSV23 after V114
Number of subjects: 407
Study: 36939180

Group type: EXPERIMENTAL
Intervention: Increased number of shoulder dislocations
Number of subjects: 892

Group type: EXPERIMENTAL
Intervention: Increasing age, male sex, non-White race
Number of subjects: 892

Group type: EXPERIMENTAL
Intervention: Contact sport participation
Number of subjects: 892

Group type: EXPERIMENTAL
Intervention: Shoulder Activity Scale
Number of subjects: 892

Group type: EXPERIMENTAL
Intervention: Positive apprehension test
Number of subjects: 892

Group type: EXPERIMENTAL
Intervention: Combined lesions
Number of subjects: 892